title: Potential therapeutic application of intravenous autologous bone marrow infusion in patients with alcoholic liver cirrhosis.
abstract: The present study was conducted to evaluate the application and efficacy of autologous bone marrow infusion (ABMi) for improvement of liver function in patients with alcoholic liver cirrhosis (ALC). Five subjects and 5 control patients with ALC who had abstained from alcohol intake for 24 weeks before the study were enrolled. Autologous bone marrow cells were washed and injected intravenously, and the changes in serum liver function parameters, and the level of the type IV collagen 7S domain as a marker of fibrosis, were monitored for 24 weeks. The distribution of activated bone marrow was assessed by indium-111-chloride bone marrow scintigraphy. The number of cells infused was 8.0±7.3×10(9) (mean±standard error). The serum levels of albumin and total protein and the prothrombin time were significantly higher during the follow-up period after ABMi than during the observation period in treated patients, whereas no such changes were observed in the controls. In the patients who received ABMi, the Child-Pugh score decreased in all 3 who were classified as class B; the serum levels of type IV collagen 7S domain improved in 4 of the 5 patients; and bone marrow scintigraphy demonstrated an increase of indium-111-chloride uptake in 3 of the 4 patients tested. ABMi for patients with ALC helps improve liver function parameters in comparison with observation during abstinence and ameliorates the degree of fibrosis in terms of serum markers and bone marrow activation in most cases.
authors.affiliation: Department of Gastroenterology, Yamagata University School of Medicine, Yamagata, Japan. tasaitoh@med.id.yamagata-u.ac.jp
authors.forename: Takafumi
authors.initials: T
authors.lastname: Saito
authors.forename: Kazuo
authors.initials: K
authors.lastname: Okumoto
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Haga
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nishise
authors.forename: Rika
authors.initials: R
authors.lastname: Ishii
authors.forename: Chikako
authors.initials: C
authors.lastname: Sato
authors.forename: Hisayoshi
authors.initials: H
authors.lastname: Watanabe
authors.forename: Akio
authors.initials: A
authors.lastname: Okada
authors.forename: Motoki
authors.initials: M
authors.lastname: Ikeda
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Togashi
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Shuji
authors.initials: S
authors.lastname: Terai
authors.forename: Isao
authors.initials: I
authors.lastname: Sakaida
authors.forename: Sumio
authors.initials: S
authors.lastname: Kawata
mesh_terms: D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D001798:Blood Proteins / Q000378:metabolism; D016026:Bone Marrow Transplantation; D024141:Collagen Type IV / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008099:Liver / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008104:Liver Cirrhosis, Alcoholic / Q000097:blood / Q000473:pathology / Q000628:therapy*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D015703:Antigens, CD; D001798:Blood Proteins; D024141:Collagen Type IV